{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:31:04Z","timestamp":1794655864171,"version":"4.9.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The distribution of tau pathology in Alzheimer\u2019s disease (AD) shows remarkable inter-individual heterogeneity, including hemispheric asymmetry. However, the factors driving this asymmetry remain poorly understood. Here we explore whether tau asymmetry is linked to i) reduced inter-hemispheric brain connectivity (potentially restricting tau spread), or ii) asymmetry in amyloid-beta (A\u03b2) distribution (indicating greater hemisphere-specific vulnerability to AD pathology). We include 452 participants from the Swedish BioFINDER-2 cohort with evidence of both A\u03b2 pathology (CSF A\u03b242\/40 or neocortical A\u03b2-PET) and tau pathology (temporal tau-PET), categorising them as left asymmetric (n\u2009=\u2009102), symmetric (n\u2009=\u2009306), or right asymmetric (n\u2009=\u200944) based on temporal lobe tau-PET uptake distribution. We assess edge-wise inter-hemispheric functional (RSfMRI; n\u2009=\u2009318) and structural connectivity (dMRI; n\u2009=\u2009352) but find no association between tau asymmetry and connectivity. In contrast, we observe a strong association between tau and A\u03b2 laterality patterns based on PET uptake (n\u2009=\u2009233; \u03b2\u2009=\u20090.632, p\u2009&lt;\u20090.001), which we replicate in three independent cohorts (n\u2009=\u2009234; \u03b2\u2009=\u20090.535, p\u2009&lt;\u20090.001). In a longitudinal A\u03b2-positive sample, we show that baseline A\u03b2 asymmetry predicts progression of tau laterality over time (n\u2009=\u2009289; \u03b2\u2009=\u20090.025, p\u2009=\u20090.028). These findings suggest that tau asymmetry is not associated with a weaker inter-hemispheric connectivity but might reflect hemispheric differences in vulnerability to A\u03b2 pathology, underscoring the role of regional vulnerability in determining the distribution of AD pathology.<\/jats:p>","DOI":"10.1038\/s41467-025-63564-2","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:44:11Z","timestamp":1757065451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer\u2019s Disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3650-4230","authenticated-orcid":false,"given":"Toomas Erik","family":"Anij\u00e4rv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-7477","authenticated-orcid":false,"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0112","authenticated-orcid":false,"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-3337","authenticated-orcid":false,"given":"Alexa","family":"Pichet Binette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-1762","authenticated-orcid":false,"given":"Lyduine E.","family":"Collij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6729-6801","authenticated-orcid":false,"given":"Harry H.","family":"Behjat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-0166","authenticated-orcid":false,"given":"Jonathan","family":"Rittmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-772X","authenticated-orcid":false,"given":"Linda","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3371-6211","authenticated-orcid":false,"given":"Khazar","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Rivera-Mindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozioma","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur W.","family":"Toga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangsik","family":"Nho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Tosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-9874","authenticated-orcid":false,"given":"Danielle","family":"van Westen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-9940","authenticated-orcid":false,"given":"Jacob W.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-8788","authenticated-orcid":false,"given":"Nicola","family":"Spotorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"63564_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","volume":"94","author":"D Ferreira","year":"2020","unstructured":"Ferreira, D., Nordberg, A. & Westman, E. Biological subtypes of Alzheimer disease. Neurology 94, 436\u2013448 (2020).","journal-title":"Neurology"},{"key":"63564_CR2","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/brain\/awae118","volume":"147","author":"H Baumeister","year":"2024","unstructured":"Baumeister, H. et al. A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings. Brain 147, 2400\u20132413 (2024).","journal-title":"Brain"},{"key":"63564_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biom6010006","volume":"6","author":"G \u0160imi\u0107","year":"2016","unstructured":"\u0160imi\u0107, G. et al. Tau protein hyperphosphorylation and aggregation in Alzheimer\u2019s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 6, 6 (2016).","journal-title":"Biomolecules"},{"key":"63564_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"63564_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. & Del Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. (Berl.) 112, 389\u2013404 (2006).","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"63564_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med 27, 954\u2013963 (2021).","journal-title":"Nat. Med"},{"key":"63564_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat. Med 27, 871\u2013881 (2021).","journal-title":"Nat. Med"},{"key":"63564_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., Kant, R., van der & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"63564_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2023.103416","volume":"38","author":"J Lu","year":"2023","unstructured":"Lu, J. et al. The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer\u2019s disease. NeuroImage Clin. 38, 103416 (2023).","journal-title":"NeuroImage Clin."},{"key":"63564_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamaneurol.2022.0676","volume":"79","author":"CB Young","year":"2022","unstructured":"Young, C. B. et al. Divergent cortical tau positron emission tomography patterns among patients with preclinical Alzheimer disease. JAMA Neurol. 79, 592\u2013603 (2022).","journal-title":"JAMA Neurol."},{"key":"63564_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bbi.2024.05.002","volume":"119","author":"K Younes","year":"2024","unstructured":"Younes, K. et al. Temporal tau asymmetry spectrum influences divergent behavior and language patterns in Alzheimer\u2019s disease. Brain Behav. Immun. 119, 807\u2013817 (2024).","journal-title":"Brain Behav. Immun."},{"key":"63564_CR12","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00702-015-1410-8","volume":"122","author":"A King","year":"2015","unstructured":"King, A., Bodi, I., Nolan, M., Troakes, C. & Al-Sarraj, S. Assessment of the degree of asymmetry of pathological features in neurodegenerative diseases. What is the significance for brain banks?. J. Neural Transm. 122, 1499\u20131508 (2015).","journal-title":"J. Neural Transm."},{"key":"63564_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/jnen\/nlac008","volume":"81","author":"C Tremblay","year":"2022","unstructured":"Tremblay, C. et al. Hemispheric asymmetry and atypical lobar progression of alzheimer-type tauopathy. J. Neuropathol. Exp. Neurol. 81, 158\u2013171 (2022).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"63564_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","volume":"13","author":"SJ Crutch","year":"2017","unstructured":"Crutch, S. J. et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement 13, 870\u2013884 (2017).","journal-title":"Alzheimers Dement"},{"key":"63564_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014 (2011).","journal-title":"Neurology"},{"key":"63564_CR16","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016).","journal-title":"Brain"},{"key":"63564_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3233\/JAD-170740","volume":"62","author":"KA Tetzloff","year":"2018","unstructured":"Tetzloff, K. A. et al. Regional distribution, asymmetry, and clinical correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer\u2019s Disease. J. Alzheimers Dis. 62, 1713\u20131724 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"63564_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40478-022-01412-w","volume":"10","author":"A Martersteck","year":"2022","unstructured":"Martersteck, A. et al. Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology. Acta Neuropathol. Commun. 10, 111 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"63564_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel, J. W. et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat. Commun. 11, 2612 (2020).","journal-title":"Nat. Commun."},{"key":"63564_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118126","volume":"237","author":"F Yang","year":"2021","unstructured":"Yang, F. et al. Longitudinal predictive modeling of tau progression along the structural connectome. NeuroImage 237, 118126 (2021).","journal-title":"NeuroImage"},{"key":"63564_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14159-1","volume":"11","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier, N. et al. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer\u2019s disease. Nat. Commun. 11, 347 (2020).","journal-title":"Nat. Commun."},{"key":"63564_CR22","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/alz.12867","volume":"19","author":"A Steward","year":"2023","unstructured":"Steward, A. et al. Functional network segregation is associated with attenuated tau spreading in Alzheimer\u2019s disease. Alzheimers Dement 19, 2034\u20132046 (2023).","journal-title":"Alzheimers Dement"},{"key":"63564_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/brain\/awx347","volume":"141","author":"TE Cope","year":"2018","unstructured":"Cope, T. E. et al. Tau burden and the functional connectome in Alzheimer\u2019s disease and progressive supranuclear palsy. Brain 141, 550\u2013567 (2018).","journal-title":"Brain"},{"key":"63564_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci. Adv. 6, eaaz2387 (2020).","journal-title":"Sci. Adv."},{"key":"63564_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette, A. et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat. Commun. 13, 6635 (2022).","journal-title":"Nat. Commun."},{"key":"63564_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh1448","volume":"7","author":"G Meisl","year":"2021","unstructured":"Meisl, G. et al. In vivo rate-determining steps of tau seed accumulation in Alzheimer\u2019s disease. Sci. Adv. 7, eabh1448 (2021).","journal-title":"Sci. Adv."},{"key":"63564_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80, 247\u2013258 (2016).","journal-title":"Ann. Neurol."},{"key":"63564_CR28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy, A. et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurol. 77, 955\u2013965 (2020).","journal-title":"JAMA Neurol."},{"key":"63564_CR29","doi-asserted-by":"crossref","unstructured":"LaMontagne P. J. et al. OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease. Published online December 15, 2019.12.13.19014902. (2019).","DOI":"10.1101\/2019.12.13.19014902"},{"key":"63564_CR30","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling, R. A. et al. The A4 Study: Stopping AD Before Symptoms Begin?. Sci. Transl. Med 6, 228fs13\u2013228fs13 (2014).","journal-title":"Sci. Transl. Med"},{"key":"63564_CR31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/acn3.51048","volume":"7","author":"PS Insel","year":"2020","unstructured":"Insel, P. S., Donohue, M. C., Sperling, R., Hansson, O. & Mattsson-Carlgren, N. The A4 study: \u03b2-amyloid and cognition in 4432 cognitively unimpaired adults. Ann. Clin. Transl. Neurol. 7, 776\u2013785 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"63564_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen, R. C. et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Neurology 74, 201\u2013209 (2010).","journal-title":"Neurology"},{"key":"63564_CR33","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ajpath.2017.03.011","volume":"187","author":"RE Bennett","year":"2017","unstructured":"Bennett, R. E. et al. Enhanced Tau Aggregation in the Presence of Amyloid \u03b2. Am. J. Pathol. 187, 1601\u20131612 (2017).","journal-title":"Am. J. Pathol."},{"key":"63564_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15120-3","volume":"11","author":"SS Kwak","year":"2020","unstructured":"Kwak, S. S. et al. Amyloid-\u03b242\/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer\u2019s disease. Nat. Commun. 11, 1377 (2020).","journal-title":"Nat. Commun."},{"key":"63564_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway, J. M. et al. Clearance systems in the brain\u2014implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457\u2013470 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"63564_CR36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211275","volume":"219","author":"K Ishida","year":"2022","unstructured":"Ishida, K. et al. Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. J. Exp. Med 219, e20211275 (2022).","journal-title":"J. Exp. Med"},{"key":"63564_CR37","first-page":"232","volume":"10","author":"L Lemoine","year":"2018","unstructured":"Lemoine, L., Leuzy, A., Chiotis, K., Rodriguez-Vieitez, E. & Nordberg, A. Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. Alzheimers Dement Diagn. Assess. Dis. Monit. 10, 232 (2018).","journal-title":"Alzheimers Dement Diagn. Assess. Dis. Monit."},{"key":"63564_CR38","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","volume":"59","author":"H Kuwabara","year":"2018","unstructured":"Kuwabara, H. et al. Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. J. Nucl. Med 59, 1877 (2018).","journal-title":"J. Nucl. Med"},{"key":"63564_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00401-024-02801-2","volume":"148","author":"T Freiburghaus","year":"2024","unstructured":"Freiburghaus, T. et al. Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions. Acta Neuropathol. (Berl.) 148, 44 (2024).","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"63564_CR40","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaneurol.2018.3692","volume":"76","author":"R Smith","year":"2019","unstructured":"Smith, R., Wibom, M., Pawlik, D., Englund, E. & Hansson, O. Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. JAMA Neurol. 76, 310\u2013317 (2019).","journal-title":"JAMA Neurol."},{"key":"63564_CR41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/RLU.0000000000003662","volume":"46","author":"HJ Yoon","year":"2021","unstructured":"Yoon, H. J. et al. Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease. Clin. Nucl. Med 46, 527\u2013531 (2021).","journal-title":"Clin. Nucl. Med"},{"key":"63564_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbas.2022.100048","volume":"2","author":"PL Kjeldsen","year":"2022","unstructured":"Kjeldsen, P. L. et al. Asymmetric amyloid deposition in preclinical Alzheimer\u2019s disease: A PET study. Aging Brain 2, 100048 (2022).","journal-title":"Aging Brain"},{"key":"63564_CR43","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1093\/brain\/awv229","volume":"138","author":"L Frings","year":"2015","unstructured":"Frings, L. et al. Asymmetries of amyloid-\u03b2 burden and neuronal dysfunction are positively correlated in Alzheimer\u2019s disease. Brain 138, 3089\u20133099 (2015).","journal-title":"Brain"},{"key":"63564_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ana.24566","volume":"79","author":"A Martersteck","year":"2016","unstructured":"Martersteck, A. et al. Is in vivo amyloid distribution asymmetric in primary progressive aphasia?. Ann. Neurol. 79, 496\u2013501 (2016).","journal-title":"Ann. Neurol."},{"key":"63564_CR45","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/brain\/aws327","volume":"136","author":"M Lehmann","year":"2013","unstructured":"Lehmann, M. et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer\u2019s disease. Brain J. Neurol. 136, 844\u2013858 (2013).","journal-title":"Brain J. Neurol."},{"key":"63564_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209920","volume":"103","author":"AD Lam","year":"2024","unstructured":"Lam, A. D. et al. Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures. Neurology 103, e209920 (2024).","journal-title":"Neurology"},{"key":"63564_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/alz.091956","volume":"20","author":"A Charil","year":"2024","unstructured":"Charil, A. et al. Lecanemab Slows Tau PET Accumulation. Alzheimers Dement 20, e091956 (2024).","journal-title":"Alzheimers Dement"},{"key":"63564_CR48","doi-asserted-by":"publisher","unstructured":"Milloz A. et al. Multiscale Quantification of Hemispheric Asymmetry in Cortical Maps Using Geometric Eigenmodes. In: 2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI).; 1\u20135. https:\/\/doi.org\/10.1109\/ISBI60581.2025.10980761 (2025).","DOI":"10.1109\/ISBI60581.2025.10980761"},{"key":"63564_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"63564_CR50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"63564_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in Early Alzheimer\u2019s Disease. N. Engl. J. Med 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med"},{"key":"63564_CR52","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat. Aging 3, 1079\u20131090 (2023).","journal-title":"Nat. Aging"},{"key":"63564_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin. Chem. Lab Med CCLM 60, 207\u2013219 (2022).","journal-title":"Clin. Chem. Lab Med CCLM"},{"key":"63564_CR54","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1093\/brain\/awac004","volume":"145","author":"EM Coomans","year":"2022","unstructured":"Coomans, E. M. et al. Genetically identical twins show comparable tau PET load and spatial distribution. Brain 145, 3571\u20133581 (2022).","journal-title":"Brain"},{"key":"63564_CR55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/jamiaopen\/ooy012","volume":"1","author":"TJ Pollard","year":"2018","unstructured":"Pollard, T. J., Johnson, A. E. W., Raffa, J. D. & Mark, R. G. tableone: An open source Python package for producing summary statistics for research papers. JAMIA Open 1, 26\u201331 (2018).","journal-title":"JAMIA Open"},{"key":"63564_CR56","doi-asserted-by":"publisher","unstructured":"Seabold S., Perktold J. Statsmodels: Econometric and Statistical Modeling with Python. In; 92\u201396. https:\/\/doi.org\/10.25080\/Majora-92bf1922-011 (2010).","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"63564_CR57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s42003-020-0794-7","volume":"3","author":"R Vos de Wael","year":"2020","unstructured":"Vos de Wael, R. et al. BrainSpace: a toolbox for the analysis of macroscale gradients in neuroimaging and connectomics datasets. Commun. Biol. 3, 103 (2020).","journal-title":"Commun. Biol."},{"key":"63564_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70978-z","volume":"10","author":"SH Cho","year":"2020","unstructured":"Cho, S. H. et al. Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Sci. Rep. 10, 14950 (2020).","journal-title":"Sci. Rep."},{"key":"63564_CR59","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.dib.2017.10.024","volume":"15","author":"SL Baker","year":"2017","unstructured":"Baker, S. L., Maass, A. & Jagust, W. J. Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. Data Brief. 15, 648\u2013657 (2017).","journal-title":"Data Brief."},{"key":"63564_CR60","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell, L. et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J. Nucl. Med Publ. Soc. Nucl. Med 55, 1623\u20131628 (2014).","journal-title":"J. Nucl. Med Publ. Soc. Nucl. Med"},{"key":"63564_CR61","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaneurol.2019.2214","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. & Hansson, O. Staging \u03b2-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 76, 1319\u20131329 (2019).","journal-title":"JAMA Neurol."},{"key":"63564_CR62","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0271678X221141139","volume":"43","author":"K Ahmadi","year":"2023","unstructured":"Ahmadi, K. et al. Gray matter hypoperfusion is a late pathological event in the course of Alzheimer\u2019s disease. J. Cereb. Blood Flow. Metab. J. Int Soc. Cereb. Blood Flow. Metab. 43, 565\u2013580 (2023).","journal-title":"J. Cereb. Blood Flow. Metab. J. Int Soc. Cereb. Blood Flow. Metab."},{"key":"63564_CR63","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl, B. FreeSurfer. NeuroImage 62, 774\u2013781 (2012).","journal-title":"NeuroImage"},{"key":"63564_CR64","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.neuroimage.2011.09.015","volume":"62","author":"M Jenkinson","year":"2012","unstructured":"Jenkinson, M., Beckmann, C. F., Behrens, T. E. J., Woolrich, M. W. & Smith, S. M. FSL. NeuroImage 62, 782\u2013790 (2012).","journal-title":"NeuroImage"},{"key":"63564_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.116137","volume":"202","author":"JD Tournier","year":"2019","unstructured":"Tournier, J. D. et al. MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation. NeuroImage 202, 116137 (2019).","journal-title":"NeuroImage"},{"key":"63564_CR66","doi-asserted-by":"publisher","unstructured":"Jon Clucas. et al. FCP-INDI\/C-PAC: C-PAC Version 1.3.0.post2 Beta. Published online May 14, 2024. https:\/\/doi.org\/10.5281\/ZENODO.593145 (2024).","DOI":"10.5281\/ZENODO.593145"},{"key":"63564_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1006\/cbmr.1996.0014","volume":"29","author":"RW Cox","year":"1996","unstructured":"Cox, R. W. AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed. Res 29, 162\u2013173 (1996).","journal-title":"Comput Biomed. Res"},{"key":"63564_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87564-6","volume":"11","author":"NJ Tustison","year":"2021","unstructured":"Tustison, N. J. et al. The ANTsX ecosystem for quantitative biological and medical imaging. Sci. Rep. 11, 9068 (2021).","journal-title":"Sci. Rep."},{"key":"63564_CR69","doi-asserted-by":"publisher","unstructured":"Abraham A. et al. Machine learning for neuroimaging with scikit-learn. Front Neuroinformatics. 8. https:\/\/doi.org\/10.3389\/fninf.2014.00014 (2014).","DOI":"10.3389\/fninf.2014.00014"},{"key":"63564_CR70","doi-asserted-by":"publisher","unstructured":"Esteban O. et al. nipy\/nipype: 1.8.3. Published online July 14, https:\/\/doi.org\/10.5281\/zenodo.6834519 (2022).","DOI":"10.5281\/zenodo.6834519"},{"key":"63564_CR71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/brain.2011.0008","volume":"1","author":"KJ Friston","year":"2011","unstructured":"Friston, K. J. Functional and effective connectivity: a review. Brain Connect 1, 13\u201336 (2011).","journal-title":"Brain Connect"},{"key":"63564_CR72","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 31, 968\u2013980 (2006).","journal-title":"NeuroImage"},{"key":"63564_CR73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0896-6273(02)00569-X","volume":"33","author":"B Fischl","year":"2002","unstructured":"Fischl, B. et al. Whole Brain Segmentation: Automated Labeling of Neuroanatomical Structures in the Human Brain. Neuron 33, 341\u2013355 (2002).","journal-title":"Neuron"},{"key":"63564_CR74","unstructured":"Dhollander T., Mito R., Raffelt D., Connelly A. Improved white matter response function estimation for 3-tissue constrained spherical deconvolution. In: Proc Intl Soc Mag Reson Med, 2019, 555. (2019)."},{"key":"63564_CR75","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.neuroimage.2014.07.061","volume":"103","author":"B Jeurissen","year":"2014","unstructured":"Jeurissen, B., Tournier, J. D., Dhollander, T., Connelly, A. & Sijbers, J. Multi-tissue constrained spherical deconvolution for improved analysis of multi-shell diffusion MRI data. NeuroImage 103, 411\u2013426 (2014).","journal-title":"NeuroImage"},{"key":"63564_CR76","unstructured":"Smith R., Skoch A., Bajada C., Caspers S., Connelly A. Hybrid Surface-Volume Segmentation for improved Anatomically-Constrained Tractography. In: Proceedings of the Oganisation for Human Brain Mapping. (2020)."},{"key":"63564_CR77","unstructured":"Tournier J. D., Calamante F., Connelly A. Improved probabilistic streamlines tractography by 2nd order integration over fibre orientation distributions. In: Proceedings of the International Society for Magnetic Resonance in Medicine, 2010, 1670. (2010)."},{"key":"63564_CR78","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.neuroimage.2012.06.005","volume":"62","author":"RE Smith","year":"2012","unstructured":"Smith, R. E., Tournier, J. D., Calamante, F. & Connelly, A. Anatomically-constrained tractography: Improved diffusion MRI streamlines tractography through effective use of anatomical information. NeuroImage 62, 1924\u20131938 (2012).","journal-title":"NeuroImage"},{"key":"63564_CR79","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.neuroimage.2015.06.092","volume":"119","author":"RE Smith","year":"2015","unstructured":"Smith, R. E., Tournier, J. D., Calamante, F. & Connelly, A. SIFT2: Enabling dense quantitative assessment of brain white matter connectivity using streamlines tractography. NeuroImage 119, 338\u2013351 (2015).","journal-title":"NeuroImage"},{"key":"63564_CR80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/jmrb.1994.1037","volume":"103","author":"PJ Basser","year":"1994","unstructured":"Basser, P. J., Mattiello, J. & Lebihan, D. Estimation of the Effective Self-DiffusionTensor from the NMR Spin Echo. J. Magn. Reson B 103, 247\u2013254 (1994).","journal-title":"J. Magn. Reson B"},{"key":"63564_CR81","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0006-3495(94)80775-1","volume":"66","author":"PJ Basser","year":"1994","unstructured":"Basser, P. J., Mattiello, J. & LeBihan, D. MR diffusion tensor spectroscopy and imaging. Biophys. J. 66, 259\u2013267 (1994).","journal-title":"Biophys. J."},{"key":"63564_CR82","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neuroimage.2018.07.070","volume":"183","author":"J Wasserthal","year":"2018","unstructured":"Wasserthal, J., Neher, P. & Maier-Hein, K. H. TractSeg - Fast and accurate white matter tract segmentation. NeuroImage 183, 239\u2013253 (2018).","journal-title":"NeuroImage"},{"key":"63564_CR83","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.neuroimage.2010.06.041","volume":"53","author":"A Zalesky","year":"2010","unstructured":"Zalesky, A., Fornito, A. & Bullmore, E. T. Network-based statistic: Identifying differences in brain networks. NeuroImage 53, 1197\u20131207 (2010).","journal-title":"NeuroImage"},{"key":"63564_CR84","first-page":"180","volume":"11","author":"Y Su","year":"2019","unstructured":"Su, Y. et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement Diagn. Assess. Dis. Monit. 11, 180\u2013190 (2019).","journal-title":"Alzheimers Dement Diagn. Assess. Dis. Monit."},{"key":"63564_CR85","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","volume":"72","author":"S Schreiber","year":"2015","unstructured":"Schreiber, S., Landau, S. M., Fero, A., Schreiber, F. & Jagust, W. J. for the Alzheimer\u2019s Disease Neuroimaging Initiative. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. JAMA Neurol. 72, 1183\u20131190 (2015).","journal-title":"JAMA Neurol."},{"key":"63564_CR86","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"63564_CR87","doi-asserted-by":"publisher","unstructured":"Anij\u00e4rv T. E. teanijarv\/phd-neurodegeneration-imaging: 1.0.0. Published online August 7, 2025. https:\/\/doi.org\/10.5281\/ZENODO.16759856 (2025).","DOI":"10.5281\/ZENODO.16759856"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63564-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:02:43Z","timestamp":1757070163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63564-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63564"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63564-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.15.648728","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.H. is an employee of Eli Lilly and Lund University. R.S. has received consultancy\/speaker fees from Eli Lilly, Novo Nordisk, Roche and Triolab. S.P. has acquired research support (for the institution) from ki elements \/ ADDF and Avid. In the past 2 years, he has received consultancy\/speaker fees from Bioartic, Esai, Eli Lilly, Novo Nordisk, and Roche. N.M.C. has received consultancy\/speaker fees from Biogen, Eli Lilly, Owkin, and Merck. The precursor of [\n                      18\n                      F]flutemetamol was sponsored by GE Healthcare. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8232"}}